Would you consider immunotherapy in high-risk resectable MSI-H colorectal cancer?

Immunotherapy demonstrated great activity in treating metastatic MSI-H colorectal cancer (CheckMate 142 study, KEYNOTE-177 study, etc). There are now several small studies showing the activity of immunotherapy in early stage or locally advanced colorectal cancer.

The NICHE study enrolled 40 patients (21 dMMR and 20 pMMR colon cancer patients). All patients had 1 dose of ipilimumab (1mg/kg on day 1) and 2 doses of nivolumab (3mg/kg on days 1 and 15) then all patients underwent surgery 6 weeks aft...